Drug Type CRISPR/Cas9 |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization SparingVision SASStartup |
Active Organization SparingVision SASStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinitis Pigmentosa | Preclinical | FR | SparingVision SASStartup | 27 Mar 2022 |